| Ytd | -79.72% | |
| 1y | -92.52% |
| Open | 0.41 | Prev Close | 0.41 | Low | 0.41 | High | 0.42 | Mkt Cap | 2.44M |
| Vol | 43.51K | Avg Vol | 1.65M | EPS | -2.14 | P/E | -0.19 | Forward P/E | -9.31 |
| Beta | 6.16 | Short Ratio | 0.66 | Inst. Own | 13.72% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 0.56 | 200-d Avg | 1.54 | 1yr Est | 6.30 |
VVOS News
Gainers Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
LITTLETON, Colo., June 30, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan
Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-m
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical
Vivos and Streeterville Extend Timeframe of Financing Agreement and Reaffirm Commitment to Convert D
LITTLETON, Colo., June 11, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan
Vivos Announces Collaboration Agreement with Florida Cardiology Group to Extend Sleep Apnea and Inso
LITTLETON, Colo., June 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compan
Vivos Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Stre
Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript
Year-over-year revenue increased 70%, reflecting contribution from Vivos' acquisition of The Sleep C
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in
Wall Street analysts changed their outlook on top names. For all rating changes, see analyst ratings
Vivos Therapeutics (NASDAQ: VVOS) executives told investors the company's shift toward a medical pro
Vivos Therapeutics, Inc. (VVOS) Q4 2025 Earnings Call Transcript
Full Year 2025 revenue increased 16% Integration of The Sleep Center of Nevada and shift in business
LITTLETON, Colo., April 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Compa
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) was the target of a large decline in short
LITTLETON, Colo., April 07, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Compa
Applied Optoelectronics Inc (NASDAQ: AAOI) rose in pre-market trading after securing an 800G transce
U.S. stocks mixed, Cheer Holding announces reverse stock split, Vivos Therapeutics gains investor st
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) major shareholder Michael Skaff bought 1,3
Vivos Therapeutics Reports that Supported Professional Practices Have Achieved 'In-Network' Status A
Vivos Therapeutics, Inc. (NASDAQ: VVOS - Get Free Report) shares traded up 1.5% during trading on We
LITTLETON, Colo., March 17, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Compa
Vivos Therapeutics and SoundHealth Announce Collaboration to Expand Access to SoundHealth's Groundbr
During the session on Thursday, 461 stocks hit new 52-week lows.
Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report q
On Thursday, 241 companies hit new 52-week lows.
On Thursday, 1076 companies hit new 52-week lows.
Companies Reporting Before The Bell • Edible Garden (NASDAQ:EDBL) is likely to report earnings f
On Monday, 721 companies achieved new lows for the year.
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report